dc.contributor.author |
Accinelli Tanaka, Roberto Alfonso |
|
dc.contributor.author |
Ynga-Meléndez, G.J. |
|
dc.contributor.author |
Leon-Abarca, Juan Alonso |
|
dc.contributor.author |
Lopez Oropeza, Lidia Marianella |
|
dc.contributor.author |
Madrid-Cisneros, J.C. |
|
dc.contributor.author |
Mendoza-Saldaña, J.D. |
|
dc.date.accessioned |
2021-12-12T20:24:54Z |
|
dc.date.available |
2021-12-12T20:24:54Z |
|
dc.date.issued |
2021 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/10201 |
|
dc.description.abstract |
Background: Currently, there is no formally accepted pharmacological treatment for COVID-19. Materials and methods: We included COVID-19 outpatients of a Peruvian primary care center from Lima, Peru, who were treated between April 30 - September 30, 2020, with hydroxychloroquine and azithromycin. Logistic regression was applied to determine factors associated with case-fatality rate. Results: A total of 1265 COVID-19 patients with an average age of 44.5 years were studied. Women represented 50.1% of patients, with an overall 5.9 symptom days, SpO2 97%, temperature of 37.3 °C, 41% with at least one comorbidity and 96.1% one symptom or sign. No patient treated within the first 72 h of illness died. The factors associated with higher case fatality rate were age (OR = 1.06; 95% CI 1.01–1.11, p = 0.021), SpO2 (OR = 0.87; 95% CI 0.79–0.96, p = 0.005) and treatment onset (OR = 1.16; 95% CI 1.06–1.27, p = 0.002), being the latter the only associated in the multivariate analysis (OR = 1.18; 95% CI 1.05–1.32, p = 0.005). 0.6% of our patients died. Conclusions: The case fatality rate in COVID-19 outpatients treated with hydroxychloroquine/azithromycin was associated with the number of days of illness on which treatment was started |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Elsevier |
|
dc.relation.ispartofseries |
Travel Medicine and Infectious Disease |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
abdominal pain |
en_US |
dc.subject |
adult |
en_US |
dc.subject |
aged |
en_US |
dc.subject |
ageusia |
en_US |
dc.subject |
anosmia |
en_US |
dc.subject |
arthralgia |
en_US |
dc.subject |
Article |
en_US |
dc.subject |
azithromycin |
en_US |
dc.subject |
Azithromycin |
en_US |
dc.subject |
backache |
en_US |
dc.subject |
body temperature |
en_US |
dc.subject |
case fatality rate |
en_US |
dc.subject |
child |
en_US |
dc.subject |
chill |
en_US |
dc.subject |
clinical feature |
en_US |
dc.subject |
comorbidity |
en_US |
dc.subject |
coronavirus disease 2019 |
en_US |
dc.subject |
coughing |
en_US |
dc.subject |
COVID-19 |
en_US |
dc.subject |
decreased appetite |
en_US |
dc.subject |
diarrhea |
en_US |
dc.subject |
disease duration |
en_US |
dc.subject |
dizziness |
en_US |
dc.subject |
drug withdrawal |
en_US |
dc.subject |
dyspnea |
en_US |
dc.subject |
eye redness |
en_US |
dc.subject |
female |
en_US |
dc.subject |
fever |
en_US |
dc.subject |
headache |
en_US |
dc.subject |
human |
en_US |
dc.subject |
hydroxychloroquine |
en_US |
dc.subject |
Hydroxychloroquine |
en_US |
dc.subject |
infant |
en_US |
dc.subject |
irritability |
en_US |
dc.subject |
major clinical study |
en_US |
dc.subject |
male |
en_US |
dc.subject |
Mortality |
en_US |
dc.subject |
myalgia |
en_US |
dc.subject |
nausea |
en_US |
dc.subject |
newborn |
en_US |
dc.subject |
nose obstruction |
en_US |
dc.subject |
outpatient care |
en_US |
dc.subject |
pain |
en_US |
dc.subject |
Peru |
en_US |
dc.subject |
Peruvian |
en_US |
dc.subject |
primary medical care |
en_US |
dc.subject |
rash |
en_US |
dc.subject |
SARS-CoV-2 |
en_US |
dc.subject |
sore throat |
en_US |
dc.subject |
thorax pain |
en_US |
dc.subject |
time to treatment |
en_US |
dc.subject |
Time-to-Treatment |
en_US |
dc.subject |
unspecified side effect |
en_US |
dc.subject |
very elderly |
en_US |
dc.subject |
vomiting |
en_US |
dc.title |
Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1016/j.tmaid.2021.102163 |
|
dc.relation.issn |
1873-0442 |
|